Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | USP2 | O75604 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RGS12 | O14924 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734647 | 0.81 | ALDH1A1 (0.43) | IDO1MAPTPOLBPARP1ALDH1A1 | |
| SCHEMBL29656653 | 0.81 | ALDH1A1 (0.43) | IDO1MAPTPOLBPARP1ALDH1A1 | |
| SCHEMBL21733906 | 0.78 | PTPN1 (0.44) | MAPTPOLBCYP1A2PARP1CYP2C9 | |
| SCHEMBL29533046 | 0.78 | PTPN1 (0.44) | MAPTPOLBCYP1A2PARP1CYP2C9 | |
| SCHEMBL28773698 | 0.71 | KDM4E (0.50) | KMT2AMAPTMEN1POLBALDH1A1 | |
| SCHEMBL31678641 | 0.70 | ALDH1A1 (0.39) | MAPTPOLBALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14124657 | 0.70 | GAA (0.43) | MAPTPOLBALDH1A1SMN1; SMN2DYRK1A | |
| SCHEMBL11116210 | 0.70 | PTPN1 (0.44) | KMT2AMAPTMEN1POLBPARP1 | |
| SCHEMBL679561 | 0.70 | NPC1 (0.47) | MAPTPOLBALDH1A1HTTHPGD | |
| SCHEMBL28943980 | 0.69 | CCNE2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1690854-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7026476-B2 | Intermediate arylamine compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-7019006-B2 | Modulating release of inflammatory cytokines by administering, e.g., a 1-(5-tert-butyl-2-methyl-phenyl)-3-(6-((3-methoxy-propyl)-methylaminopyridin-3-yl)phthalen-1-yl) urea or thiourea; treating a neutrophil-mediated disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1466906-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1165516-B1 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2004-10-06 | — | — | EP | disclosed |
| US-6743788-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; AUTOIMMUNE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-01 | — | — | US | disclosed |
| EP-1395561-A1 | CARBAMATE AND OXAMIDE COMPOUNDS AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-03-10 | — | — | EP | disclosed |
| US-20040019038-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1381594-A1 | UREA COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6660732-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-6608052-B2 | An mono or polycyclic aromatic or heteroaromatic carbamate or urea or thiacarbamoyl derivatives; inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20030092702-A1 | Novel carbamate and oxamide compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | US | disclosed |
| WO-2002096876-A1 | CARBAMATE AND OXAMIDE COMPOUNDS AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002083642-A1 | COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-06-27 | — | — | US | disclosed |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-05-09 | — | — | US | disclosed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | disclosed |
| EP-1165516-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | MPO, EPX, PTGES | KEAP1 235/4885NFE2L2 67/4885CRHBP 2734/4885 |
| US-20030092702-A1 | Novel carbamate and oxamide compounds | IFNG, CXCR1, ARG1 | KEAP1 2222/4885NFE2L2 1031/4885CRHBP 4176/4885 |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | KEAP1 431/4885NFE2L2 96/4885CRHBP 2826/4885 |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | KEAP1 431/4885NFE2L2 96/4885CRHBP 2826/4885 |
| US-20040019038-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | KEAP1 431/4885NFE2L2 96/4885CRHBP 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.